NFE2L2 and Alzheimer disease: Recently, (Tang et al. 2024) demonstrated that administering EGCG at a dose of 50 mg/kg significantly reduced oxidative stress in Alzheimer's disease models by activating the Keap1/Nrf2 signaling pathway.